Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Beltropolis Boy who wrote (1150)	10/21/1999 6:20:00 PM
From: taxman	Respond to of 1686

your quote confirmed by cbs marketwatch. regards [BGEN] BIOGEN TRADING DOWN 10 9/16 TO 62 IN AFTER-HOURS TRADING

To: Beltropolis Boy who wrote (1150)	10/21/1999 8:04:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1686

Chris: I haven't owned BGEN for about 10 years, so this doesn't hurt the wallet. However, I'm very bummed. The question is, will IDPH also take it on the chin, or is there already evidence that it's an antibody-specific issue (if there's an issue at all). The competitive projects using MAbs are easy to find, but..... I've sort of just filed any reports of projects looking downstream, small molecule intracellular stuff. If it's an epitope-specific issue, BGEN may still be in the driver's seat. However, one would also think that another company could then sneak in with some new claims. Bummed, bummed, bummed. Hope this is just a hiccup for BGEN, and virtually no impediment for IDPH. Rick